Enhancement of radiation response with bevacizumab

Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971, 285: 1182-6. 10.1056/NEJM197111182852108.

Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989, 161: 851-8. 10.1016/0006-291X(89)92678-8.

Connolly DT, Olander JV, Heuvelman D, et al: Human vascular permeability factor. Isolation from U937 cells. J Biol Chem. 1989, 264: 20017-24.

Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002, 2: 795-803. 10.1038/nrc909.

Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86: 353-64. 10.1016/S0092-8674(00)80108-7.

Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004, 3: 391-400. 10.1038/nrd1381.

Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999, 59: 3374-8.

Mauceri HJ, Hanna NN, Beckett MA, et al: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 1998, 394: 287-91. 10.1038/28412.

Hanna NN, Seetharam S, Mauceri HJ, et al: Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 2000, 6: 287-93.

Li J, Huang S, Armstrong EA, Fowler JF, Harari PM: Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys. 2005, 62: 1477-85. 10.1016/j.ijrobp.2005.04.028.

Hoang T, Huang S, Armstrong E, Harari PM: Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474. Pro Am Assoc Cancer Res. 2004, 45: 955-

Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW: Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 2002, 62: 1702-6.

Zips D, Hessel F, Krause M, et al: Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys. 2005, 61: 908-14. 10.1016/j.ijrobp.2004.11.007.

Siemann DW, Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002, 53: 164-71. 10.1016/S0360-3016(02)02742-6.

Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM: Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2006, 64: 1458-65. 10.1016/j.ijrobp.2005.11.017.

Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys. 1998, 42: 899-903. 10.1016/S0360-3016(98)00320-4.

Folkman J: Tumor angiogenesis and tissue factor. Nat Med. 1996, 2: 167-8. 10.1038/nm0296-167.

Wachsberger PR, Burd R, Marero N, et al: Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res. 2005, 11: 835-42.

Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001, 7: 987-9. 10.1038/nm0901-987.

Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64: 3731-6. 10.1158/0008-5472.CAN-04-0074.

Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004, 10: 145-7. 10.1038/nm988.

Willett CG, Duda DG, di Tomaso E, et al: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009, 27: 3020-6. 10.1200/JCO.2008.21.1771.

Crane CH, Ellis LM, Abbruzzese JL, et al: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006, 24: 1145-51. 10.1200/JCO.2005.03.6780.

Seiwert TY, Haraf DJ, Cohen EE, et al: Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008, 26: 1732-41. 10.1200/JCO.2007.13.1706.